Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
Diamedica Therapeutics (DMAC) Stock Price & Analysis
423 Followers
DMAC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.12 - $3.17
Previous Close$2.75
Volume40.05K
Average Volume (3M)46.44K
Market Cap
$74.07M
Enterprise Value$41.03M
Total Cash (Recent Filing)$33.50M
Total Debt (Recent Filing)$469.00K
Price to Earnings (P/E)-4.7
Beta0.46
Next Earnings
Aug 15, 2023EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding11,956,874
10 Day Avg. Volume170,907
30 Day Avg. Volume46,436
Standard Deviation1.75
R-Squared0.00567
Alpha0.21
Financial Highlights & Ratios
Price to Book (P/B)2.75
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.98
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
Diamedica Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DMAC FAQ
What was Diamedica Therapeutics Inc’s price range in the past 12 months?
Diamedica Therapeutics Inc lowest stock price was $1.12 and its highest was $3.17 in the past 12 months.
What is Diamedica Therapeutics Inc’s market cap?
Currently, no data Available
When is Diamedica Therapeutics Inc’s upcoming earnings report date?
Diamedica Therapeutics Inc’s upcoming earnings report date is Aug 15, 2023 which is in 79 days.
How were Diamedica Therapeutics Inc’s earnings last quarter?
Diamedica Therapeutics Inc released its earnings results on May 15, 2023. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.16 by -$0.04.
Is Diamedica Therapeutics Inc overvalued?
According to Wall Street analysts Diamedica Therapeutics Inc’s price is currently Overvalued.
Does Diamedica Therapeutics Inc pay dividends?
Diamedica Therapeutics Inc does not currently pay dividends.
What is Diamedica Therapeutics Inc’s EPS estimate?
Diamedica Therapeutics Inc’s EPS estimate is -$0.2.
How many shares outstanding does Diamedica Therapeutics Inc have?
Diamedica Therapeutics Inc has 26,933,727 shares outstanding.
What happened to Diamedica Therapeutics Inc’s price movement after its last earnings report?
Diamedica Therapeutics Inc reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.16. Following the earnings report the stock price went down -11.055%.
Which hedge fund is a major shareholder of Diamedica Therapeutics Inc?
Currently, no hedge funds are holding shares in DMAC
---
Diamedica Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 5.1%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.54%
12-Months-Change
Fundamentals
Return on Equity
-45.55%
Trailing 12-Months
Asset Growth
-28.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Diamedica Therapeutics Inc
DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS), and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
---
Top 5 ETFs holding DMAC
iShares Core S&P Total U.S. Stock Market ETF
$24.78K
Up to five ETFs with an Outperform Smart Score that hold DMAC. The ETFs are listed according to market value of DMAC within the ETF
---
Acurx Pharmaceuticals
―
Eledon Pharmaceuticals
―
TRACON Pharmaceuticals
―
BioCardia
―
Monopar Therapeutics Inc
―
---